Neuland Laboratories Ltd. (NEULANDLAB) fundamentals
Neuland Laboratories Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as NEULANDLAB (ISIN INE794A01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Neuland Laboratories Ltd. does
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Valuation and market data
| Last close | ₹19055.00 |
|---|---|
| Market capitalisation | ₹24,448 crore |
| Enterprise value | ₹24,716 crore |
| P/E (TTM) | 67.16 |
| Price to book | 13.04 |
| Price to sales (TTM) | 6.72 |
| Book value per share | ₹1461.01 |
| Dividend yield | 17.84% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Oct 13 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,053 crore | ₹489 crore | ₹364 crore | 283.71 |
| Mar 2025 | ₹1,497 crore | ₹346 crore | ₹260 crore | 202.74 |
| Mar 2024 | ₹1,571 crore | ₹401 crore | ₹300 crore | 233.89 |
| Mar 2023 | ₹1,201 crore | ₹216 crore | ₹164 crore | 127.45 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 32.3% |
|---|---|
| Foreign institutions (FII) | 21.9% |
| Mutual funds | 12.4% |
| Other domestic institutions | 3.8% |
| Retail and others | 29.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.